Blood | American Society of Hematology

Skip Nav Destination

Edimara Reis; Rebecca Buonpane; Hamza Celik; Caroline Marty; Angela Lei; Fatoumata Jobe; Mark Rupar; Yue Zhang; Darlise DiMatteo; Rahel Awdew; Bianca L Ferreira; Lynn Leffet; Lu Lu; Elodie Rosa; Maxime Evrard; Gaurang Trivedi; Brittney Wass; April Horsey; Xin He; Maryanne B Covington; Alla Volgina; Florence Pasquier; Laurence Legros; Guillemette Fouquet; William Vainchenker; Yan-ou Yang; Breann Barker; Jing Zhou; Shaun Stewart; Ian S Hitchcock; Dashyant Dhanak; Ricardo Macarron; Isabelle Plo; Horacio G Nastri; Patrick A Mayes

Matthew J. Frigault; Charlotte E. Graham; Trisha R. Berger; Julie Ritchey; Nora K. Horick; Areej El-Jawahri; Irene Scarfò; Andrea Schmidts; Nicholas J. Haradhvala; Marc Wehrli; Won-Ho Lee; Aiyana L. Parker; Hadley R. Wiggin; Amanda Bouffard; Aonkon Dey; Mark B. Leick; Katelin Katsis; Eva L. Elder; Maria A. Dolaher; Daniella T. Cook; Alena A. Chekmasova; Lu Huang; Sarah Nikiforow; Heather Daley; Jerome Ritz; Myriam Armant; Fred Preffer; John F. DiPersio; Valentina Nardi; Yi-Bin Chen; Kathleen M. E. Gallagher; Marcela V. Maus

Issue Highlights

Featured Content

CD8+ T-cell differentiation and treatment response in AML; ATM germline pathogenic variants affect cancer outcomes in ataxia-telangiectasia; efficacy of a selective menin-KMT2A inhibitor in KMT2A- and NPM1-altered leukemias

CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

ATM germ line pathogenic variants affect outcomes in children with ataxia-telangiectasia and hematological malignancies

Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in KMT2A- and NPM1-altered leukemias

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies

ASH Publications

American Society of Hematology